Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 4 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Player Avatar TMFFishBiz (34.09) Submitted: 11/8/2012 8:00:53 PM : Outperform Start Price: $10.75 AMRN Score: -107.70

Great product with Vascepa. High likelihood for acquisition by a bigger pharma (maybe AZN). Huge market potential.

Featured Broker Partners